This study presents an enhanced nuclease prime editor (uPEn) that significantly improves gene knock-in and knockout efficiency in mammalian zygotes.

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

This led to the identification of AcrVIB1, the first anti-CRISPR protein targeting the Cas13b nuclease. The nuclease Cas13b can recognize and cut RNA. It is currently used to silence genes ...

Our laboratory carried out research in two areas. In one, we studied the structure and mechanism of activity of the catalytic RNA moiety of the RNA processing enzyme ribo-nuclease P (Rnase P). In the ...

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

After hours: March 18 at 7:44:21 PM EDT Loading Chart for SANA ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...

Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I ...

Here, the authors demonstrate that the type I-B Hachiman system functions as a heterodimeric HamAB complex, in which the helicase and nuclease cooperate to counteract phage infection. DNA ...